$2.21
-0.08 (-3.49%)
Open$2.30
Previous Close$2.29
Day High$2.30
Day Low$2.20
52W High$138.60
52W Low$1.71
Volume—
Avg Volume171.7K
Market Cap1.68M
P/E Ratio—
EPS$-173.01
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,151.6% upside
Current
$2.21
$2.21
Target
$27.66
$27.66
$20.34
$27.66 avg
$35.38
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.53M | 1.54M | 1.49M |
| Net Income | 146.8K | 155.5K | 142.3K |
| Profit Margin | 9.6% | 10.1% | 9.6% |
| EBITDA | 279.3K | 246.3K | 227.4K |
| Free Cash Flow | 124.0K | 159.2K | 163.1K |
| Rev Growth | +19.5% | +5.1% | +5.0% |
| Debt/Equity | 0.44 | 0.57 | 0.57 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |